Inhibrx Biosciences Shares Q4 and Full Year Financial Outcomes for 2025 Inhibrx Biosciences has reported its financial results for Q4 and the entire fiscal year of 2025, outlining significant developments and future milestones.

Inhibrx Biosciences Shares Q4 and Full Year Financial Outcomes for 2025 #USA #San_Diego #Inhibrx_Biosciences #ozekibart #INBRX-101

Inhibrx Reports Impressive Third Quarter 2025 Financial Outcomes and Clinical Progress Inhibrx Biosciences disclosed its positive third-quarter finances for 2025, highlighting significant clinical advancements and ongoing trials.

Inhibrx Reports Impressive Third Quarter 2025 Financial Outcomes and Clinical Progress #USA #San_Diego #Inhibrx_Biosciences #INBRX-109 #Chondrosarcoma

Inhibrx Reports Second Quarter 2025 Financial Results and Future Milestones Inhibrx Biosciences, Inc. announces its financial results for Q2 2025, detailing revenue growth and pipeline updates, projecting exciting future clinical trial data.

Inhibrx Reports Second Quarter 2025 Financial Results and Future Milestones #USA #San_Diego #Clinical_Trials #Inhibrx_Biosciences #INBX

Inhibrx Biosciences Secures Loan Agreement with Oxford Finance to Enhance Clinical Programs Inhibrx Biosciences has entered into a loan agreement with Oxford Finance, providing up to $150 million to support its innovative clinical programs.

Inhibrx Biosciences Secures Loan Agreement with Oxford Finance to Enhance Clinical Programs #United_States #San_Diego #Inhibrx_Biosciences #Oxford_Finance #INBRX-109